With almost 50% of annual commercial drug approvals being Personalised Medicine (PM) and its huge potential to improve quality of life, this emerging medical sector has received increased attention from the industry and medical research, driven by health and care services, and us, the patients. Notwithstanding the power of Advanced Therapy Medicinal Products (ATMPs) to treat progressive illnesses and rare genetic conditions, their delivery on large scale is still problematic. The biopharmaceutical companies are currently struggling to meet timely delivery and, given high prices of up to $2 million per patient, prove the cost-effectiveness of their ATMP. The fragility of ATMPs combined with the impossibility for replacements due to the nature of the treatment and the advanced stages of the patient's condition are some of the bottlenecks added to a generally critical supply chain. As a consequence, ATMPs are currently used in most cases only as a last resort. ATMPs are at the intersection of multiple healthcare logistic networks and, due to th eir novelty, research around their commercialisation is still in its infancy from an operations research perspective. To accelerate technology adoption in this domain, we characterize pertinent practical challenges in a PM supply chain and then capture them in a holistic mathematical model ready for optimisation. The identified challenges and derived model will be contrasted with literature of related supply chains in terms of model formulations and suitable optimisation methods. Finally, needed technological advancements are discussed to pave the way to affordable commercialisation of PM.
|Published - 2021